SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2007. Revenues and net income for the third quarter were positively impacted by recognition of revenue associated with up-front and milestone payments from XenoPort’s collaborations with GlaxoSmithKline and Astellas Pharma Inc. Revenues for the third quarter were $35.4 million, compared to $3.1 million for the same period in 2006. Net income for the third quarter was $15.6 million, compared to a net loss of $16.3 million for the same period in 2006. At September 30, 2007, XenoPort had cash, cash equivalents and short-term investments of $159.6 million.
